Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	5.36	6.91	18.71	1.15	6.93
Research & Development	7.59	19.84	4.69	4.39	3.4
Other Operating Expenses	-2.23	-2.52	-3.53	-3.93	-1.76
Operating Expenses	10.72	24.22	19.87	1.61	8.57
Operating Income	-10.72	-24.22	-19.87	-1.61	-8.57
Interest Expense / Income	0.35	0.11	1.3	1	0.96
Other Expense / Income	-0.46	-0.16	7.92	-2.67	0.58
Pretax Income	-10.61	-24.17	-29.08	0.06	-10.1
Net Income	-10.61	-24.17	-29.08	0.06	-10.1
Preferred Dividends	0.01	0.91	0.8	0	0
Net Income Common	-10.63	-25.09	-29.89	0.06	-10.1
Shares Outstanding (Basic)	2	0	0	0	0
Shares Outstanding (Diluted)	2	0	0	0	0
Shares Change	1158.34%	114.15%	22.15%	-33.68%	314.69%
EPS (Basic)	-4.69	-139.42	-355.72	-	-9.60
EPS (Diluted)	-4.69	-139.42	-355.72	-	-9.60
Free Cash Flow	-10.78	-17.88	-8.24	-1.25	-0.94
Free Cash Flow Per Share	-4.76	-99.39	-98.10	-18.98	-9.02
EBITDA	-10.26	-24.06	-27.79	1.05	-9.14
Depreciation & Amortization	0	0	0	0	0
EBIT	-10.26	-24.06	-27.79	1.05	-9.14

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).